

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A01N 63/02 // (A01N 63/02, 25:22, 43:78)	A1	(11) International Publication Number: WO 94/13143 (43) International Publication Date: 23 June 1994 (23.06.94)
(21) International Application Number: PCT/US93/11884 (22) International Filing Date: 8 December 1993 (08.12.93) (30) Priority Data: 07/986,671 8 December 1992 (08.12.92) US (71) Applicant: APPLIED MICROBIOLOGY, INC. [US/US]; 170 53 Street, Brooklyn, NY 11232 (US). (72) Inventors: BLACKBURN, Peter; 426 West 44 Street, New York, NY 10036 (US). DE LA HARPE, Jon; 87 St. Mark's Place, New York, NY 10009 (US). (74) Agents: DRIVAS, Dimitrios, T. et al.; White & Case, 1155 Avenue of the Americas, New York, NY 10036 (US).		(81) Designated States: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: STABILIZED LANTHIONINE BACTERIOCIN COMPOSITIONS (57) Abstract The invention concerns compositions containing a lanthionine containing bacteriocin such as nisin which are stabilized by the presence of a thioether stabilizing agent against degradation. The thioester compound is preferably a compound of formula (I): R ¹ -S-R ¹ . In a preferred embodiment, the compound of formula (I) is the amino acid methionine or an analog thereof.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

STABILIZED LANTHIONINE BACTERIOCIN COMPOSITIONS

Background of the Invention

5 It is particularly difficult to maintain proteins and peptides stable for extended periods when stored at ambient temperatures, particularly in dilute solution, and this remains a major challenge for formulation chemists. Proteins and peptides can undergo degradation
10 by various pathways, including but not limited to the following: peptide bond hydrolysis particularly at extremes of pH, deamidation under acidic pH, dehydration and desulfurization at alkaline pH, halogenation of aromatic side chains, oxidation of sulfur-containing and
15 indole side chains, thiol-disulfide rearrangements, modification of amine groups by reactive carbonyl compounds and amadori rearrangements with beta-hydroxy carbonyl compounds, polymerization, precipitation, and denaturation.

20 The rate of degradation of a protein or peptide can be influenced by the sequence of adjacent amino acid residues in the molecule; for example Asn-Gly sequences are particularly susceptible to deamidation and beta-rearrangement of the intervening peptide bond. The amino
25 acid sequence, subject to environmental constraints, determines the three-dimensional structure of the molecule which can further influence the rate of degradation of a protein or peptide. The components of a formulation and their interactions can create
30 environmental conditions in the formulation which can influence the structure of a protein or peptide molecule, or they might participate directly in degradative pathways to positively or negatively affect the stability of a protein or peptide in that formulation.

35 Nisin is a bacteriocin, and in particular, is a member of a family of peptides characterized by the presence of lanthionine-containing ring structures

believed to be essential for the integrity and functionality of the molecule. Other members of this class of peptide include, but are not limited to, subtilin, duramycin, cinnamycin, ancovenin, Pep 5, epidermin and gallidermin.

Nisin and its related peptides are antimicrobial agents that, among other things, inhibit the germination and arrest the outgrowth of certain bacterial spores. In this context, a commercial nisin preparation, Nisaplin™ is marketed (Aplin & Barrett, Beaminster, U.K.) as a direct additive in foods to inhibit the growth of certain pathogens and spoilage organisms, in particular thermostable, spore-forming clostridial species that are responsible for botulism. In addition, nisin and related peptides are active against vegetative forms of certain bacteria responsible for certain diseases in animals and humans.

It has been found that when nisin and related peptide bacteriocins are combined with chelating agents and/or various surfactants, the bactericidal activity of the antimicrobial peptide in such formulations is significantly improved, and is broadened to include a much wider range of bacteria now including species of both gram negative and gram positive bacteria (see U.S. Patent No. 5,135,910, the disclosure of which is herein incorporated by reference). In addition, the performance of the peptide formulation can be further affected by the presence of various excipients and other carriers useful to facilitate delivery of the formulation to its intended site of action, for example, under physiological conditions for pharmaceutical formulations.

Adequate performance of formulations of nisin and related peptides requires that the peptide remain physically stable and biologically active in the various formulations under conditions of use and storage. Furthermore, the requirements for stability and integrity

of active agents, including biologically active peptides, are a subject for regulatory scrutiny.

It has been widely accepted that the activity of lanthionine-containing peptides is relatively stable and can even tolerate extreme temperatures. The nisin preparation, Nisaplin™, has been used under extreme temperatures, for example during pasteurization and even at the retort temperatures used in canning of certain foods. Despite this apparent stability it has been found that upon storage these bacteriocin molecules undergo degradative changes some of which, but not all, result in a loss of bioactivity. It has been shown by Chan et al. "Isolation and characterization of two degradation products derived from the peptide antibiotic nisin." FEBS Letters, Vol. 252 No. 1,2, 29-36 (July 1989) that upon storage of the spray-dried preparation Nisaplin™, nisin in the preparation undergoes degradation with the accumulation of breakdown products separable by reversed phase high performance liquid chromatography (RPHPLC) on silica-based resins eluted with gradients of organic modifiers.

Compounds as widely diverse as proteins (e.g., albumin), amino acids, surfactants, alcohols, carbohydrates and various oxygen and radical scavengers have been cited as candidates for the stabilization of peptides and proteins in solution. While nisin alone in dilute acid or a buffered solution in the pH range 2 to 5 shows good stability characteristics, it has been found that some substances such as certain emulsifiers and surfactants which enhance the bactericidal activity of lanthionine-containing bacteriocins in formulations (see U.S. Patent No. 5,135,910) may also accelerate the degradation of the bacteriocins over the course of time.

Many commonly used stabilizers and antioxidants are virtually ineffective in overcoming the degradation of lanthionine-containing peptides. Consequently, new agents were sought which would counteract the degradation

of the bacteriocins in the formulation and which would thus yield compositions of enhanced and stable shelf life.

5 Summary of the Invention

The present invention concerns compositions comprising lanthionine-containing peptide bacteriocins such as nisin stabilized by the presence of a suitable thioether compound as a stabilizer. The thioether
10 compound is preferably a compound of the formula I.



wherein R^1 is an alkyl group containing 1-6 carbon atoms or $-(CH_2)_n-CH-COOH$



and R^2 is $-(CH_2)_n-CH-R^4$



wherein n is 0 to 5; R^3 is hydrogen an amino group, or an
25 hydroxyl group; and R^4 is a hydrogen, a carboxyl group, an ester group or an amido group wherein the amino function is contributed by an amino acid residue or wherein R^1 and R^2 together are joined to form, with the sulfur, a thiazolidine ring.

30 In a preferred embodiment, the compound of formula I is the amino acid methionine or an analog thereof.

The present invention further concerns methods of stabilizing nisin and other lanthionine-containing peptides in solution and in dry mixtures. According to
35 the invention, a compound of formula I is added to a composition comprising a lanthionine-containing peptide bacteriocin in an amount sufficient to protect the lanthionine-containing bacteriocin from degradation. The stabilizer compound may be added to the lanthionine-
40 containing bacteriocin upon formulation or alternatively

it may be pre-formulated with one or more of the non-bacteriocin components prior to formulation with the bacteriocin.

5 The addition of a compound of formula I, which is preferably methionine or an analog thereof, stabilizes the active bacteriocin ingredient over a broad pH range and does not compromise in any way the potency or utility of the compositions.

10 Brief Description of the Figures

Figure 1 shows the effect of different concentrations of methionine on the stabilization of nisin in the presence of the polysorbate surfactant T-MAZ 20 at pH 6.

15 Figure 2 shows the stability of nisin formulated with polysorbate (T-MAZ 20) preincubated with methionine.

Detailed Description of the Invention:

20 Lanthionine-containing bacteriocins such as nisin can be formulated into a variety of compositions which exhibit bactericidal activity against gram negative and gram positive organisms. These bacteriocin compositions which, in addition to the bacteriocin also may contain surfactants, emulsifiers, chelating agents, humectants and other excipients such as thickening agents, flavors, 25 fragrances, abrasives and lubricants, are used in a wide variety of applications such as oral rinses, topical disinfectants, pharmaceutical compositions, dentifrices, disinfectant paper wipes, food preservatives, germicides, 30 intramammary infusions, etc. Such composition and methods for preparing them are described in U.S. Patent No. 5,135,910, whose disclosure is herein incorporated by reference.

35 The lanthionine-containing bacteriocins used in these bactericidal compositions can be selected from the group consisting of nisin, subtilin, duramycin, cinnamycin, ancovenin, Pep 5, epidermin, and gallidermin.

While the lanthionine bacteriocin is not limited to the selection of the above group, the preferred bacteriocin is nisin.

Suitable surfactants used in combination with
5 lanthionine-containing bacteriocins in such bactericidal compositions are: polyethoxylated sorbitol esters, e.g., Peg(40) sorbitan diisostearate, Tweens™; polycondensates of ethylene oxide and propylene oxide, e.g., Poloxamers, Pluronic, F127, F68; polyethoxylated hydrogenated castor
10 oil, e.g., Cremophor, El, RH40; sorbitan fatty esters; long chain imidazoline derivatives, e.g., Miranol C2M; long chain alkyl betaines, e.g., Empigon BB; long chain alkyl amidoalkyl betaines, e.g., cocamidopropylbetaine; D, L-2-pyrrolidone-5-carboxylic acid salt of ethyl-N-
15 cocyl-L-arginate, e.g., CAE; cocamidopropyl PG diammonium chloride, EGM Monoquat PTC; lauramidopropyl, e.g., Monaquat BTL; Tagat, R60, L2, O2, S2; Cetirol HE; Pyroter; Ryoto sugar; Tensopol; Tegobetaine; Incromine; Solutol HS15 and lauramine oxide.

20 The instant invention provides compositions, and methods for producing the same, which are improved over previously disclosed compositions comprising lanthionine-containing bacteriocins. The inventive compositions not only act as enhanced broad range bactericides but in
25 addition, have an extended shelf life greater than that of the prior art compositions. The inventive bacteriocin compositions containing a suitable thioether stabilizing agent may be formulated into solutions or dry compositions such as freeze-dried preparations.

30

Representative Formulations Comprising Lanthionine-Containing Bacteriocins

Bactericidal formulations for use in the present
35 invention may be formulated as disclosed in U.S. Patent No. 5,135,910. In addition, these formulations may be stabilized by the addition of suitable thioether compounds as disclosed herein, and for specific

applications excipients may be added to the formulation suited to the purposes of the commercial application. Representative formulations and ingredients are set forth below. The concentration and inclusion of the excipients
5 may be varied by those of ordinary skill in the art so as to obtain the preferred properties desired for each formulation.

(i) A nisin-containing formulation useful as an oral
10 rinse or dentifrice comprising:
ethanol or other alcohols
poloxamer, polysorbate or other emulsifier/surfactants
EDTA, citrate or other chelators
coolmint or other flavors
15 glycerol, propylene glycol or other humectants
blue dye or other colors
saccharin or other sweeteners
nisin or other lanthionine-containing bacteriocins
May also contain thickeners such as hydroxyethyl
20 cellulose and abrasives such as silica or diatomaceous
earth for use as a dentifrice. May contain xanthan gums
or stearate salts useful for formulating as a tablet.

(ii) A nisin-containing formulation useful as a topical
25 germicide comprising:
1-propanol, ethanol or other alcohols
polysorbate or other emulsifier/surfactants
propylene glycol, glycerol or other humectants
EDTA, citrate or other chelators
30 nisin or other lanthionine-containing bacteriocins
water qs

May also contain thickeners such as
polyvinylpyrrolidone, hydroxyethyl cellulose, alginates
or silicones. In addition may contain fragrances.

35

(iii) A nisin-containing formulation useful as a
deodorant comprising:

- 1-propanol, ethanol or other alcohols
polysorbate or other emulsifier/surfactants
propylene glycol, glycerol or other humectants
EDTA, citrate or other chelators
5 fragrances
nisin or other lanthionine-containing bacteriocins
water qs
- (iv) A nisin-containing formulation useful as an
10 intramammary infusion for treating mastitis comprising:
polysorbate or other emulsifier/surfactants
EDTA, citrate or other chelators
glycerol, sorbitol, propylene glycol or other humectants
nisin or other lanthionine-containing bacteriocins
15 water qs

Thioether Stabilizing Compounds

- The inventive thioether stabilizing agents are effective in increasing the stability of bacteriocins
20 such as nisin when formulated with a wide range of surfactants, chelators, emulsifiers and humectants. While different components exhibit different degrees of associated degradation, the addition of the inventive thioether stabilizing agents is expected to have a
25 beneficial effect in all situations in which a lanthionine-containing bacteriocin is formulated with such components. The thioether stabilizing agents also increase the stability of nisin in a wide variety of formulations with chelating agents in combination with
30 the humectants glycerol or sorbitol.

- According to the invention, the lanthionine-containing peptide compositions typically would have a peptide concentration in the range of 1 $\mu\text{g/ml}$ to 1000 $\mu\text{g/ml}$, preferably in the range of 30 $\mu\text{g/ml}$ to 300 $\mu\text{g/ml}$,
35 a surfactant concentration in the range of 0.1% to 10.0% and a concentration of a thioether stabilizer compound in the range of 1 mM to 50 mM. In most instances, a

stabilizer concentration in the range of 1 to 10 mM will be sufficient to maintain the initial potency of the active ingredient.

While any suitable thioether stabilizer compound may be used as a stabilizer for these bacteriocin formulations it is preferred that the stabilizing compounds of the formula I below be used:



wherein R^1 is an alkyl group containing 1-6 carbon atoms or $-(CH_2)_n-CH-COOH$
 $\quad \quad \quad |$
 $\quad \quad \quad NH_2$

and R^2 is $-(CH_2)_n-CH-R^4$
 $\quad \quad \quad |$
 $\quad \quad \quad R^3$

wherein n is 0 to 5; R^3 is hydrogen, an amino group, or an hydroxyl group; and R^4 is a hydrogen, a carboxyl group, an ester group or an amido group wherein the amino function is contributed by an amino acid residue or wherein R^1 and R^2 together are joined to form, with the sulfur, a thiazolidine ring.


Preferably the compound of formula I is methionine, an analog thereof, or a related thioether compound. Suitable compounds for use in the invention are methionine, methionine hydroxy analog, methionine methyl ester, methionine ethyl ester, thiazolidine, and lanthionine. In certain embodiments of the invention the thioether stabilizing compound may be a peptide or a polymer rich in methionine, or methionine analog residues.

According to further embodiments of the invention, the thioether stabilizing agent may be defined by the formula II described below:



II


wherein R^1 is an alkyl group containing 1-6 carbon atoms
or





10

wherein R^3 is hydrogen or



15



x is 1-3; and R^4 may be $-H$, $-CH_3$, $-CH(CH_3)_2$, $-CH_2CH(CH_3)_2$,
 $-CH(CH_3)CH_2CH_3$, $-CH_2SH$, $-CH_2CH_2SCH_3$, $-CH_2OH$, $-CH(OH)CH_3$,
 $-CH_2COOH$, $-(CH_2)_2COOH$, $-CH_2CONH_2$, $-(CH_2)_2CONH_2$, $-(CH_2)_4NH_2$,
 20 $-(CH_2)_3NHC=NH$,




25



30

or $-(CH_2)_3-$ joined with the amino group of R^3 to form a
pyrrolidine ring; and



40 wherein R^5 is hydrogen, an amino group or a hydroxyl group
and R^6 is hydrogen or $-C-R^7$ wherein R^7 is hydroxy, alkoxy



containing 1-6 carbon atoms or
$$- \left[\begin{array}{c} \text{NH}-\text{CH}-\text{R}^4 \\ | \\ \text{O}=\text{C}- \end{array} \right]_x -\text{OH} ;$$

5 and n, x and R⁴ are as defined above.

The thioether stabilizing compound must also be suitable for the intended use of the formulation. Some thioether stabilizing compounds may protect against nisin degradation; however, the usefulness of such compounds may be limited because of their odor, toxicity or carcinogenicity. Thus, the thioether stabilizer compounds must also be selected so that they are suitable for the specific commercial application and so that they do not possess adverse characteristics which cannot be remedied.

The examples set forth below demonstrate that the thioether stabilizing compounds of the invention and preferably the compounds of formula I, e.g., methionine and related compounds, are effective, while commonly used antioxidants are not, in stabilizing lanthionine-containing peptides against degradation associated with surfactant, chelating agent or humectant components of the compositions. The data indicate that the stabilizing agents not only preserve the physical integrity but also do not interfere with the biological properties of the active-ingredient peptides.

Methods of Determining Nisin Stability

The stability of nisin may be determined in a number of ways. Those used in the examples in this application were: (i) analytical reverse phase high pressure liquid chromatography and (ii) the Minimum Inhibitory Concentration Assay described below:

35 i) Analytical reverse phase high pressure liquid chromatography (RPHPLC). The analyte (nisin) in solution is passed through a column of hydrophic beads to which the nisin tends to bind. The solution

flowing through the column is then made progressively more hydrophobic by increasing acetonitrile concentration until it causes the nisin to be released from the beads and eluted from the column. The emergence of the nisin from the column is detected by measuring the absorbance of light at 210 nm by the effluent.

A second detection system may also be used in conjunction with RPHPLC, by reacting amine-containing components emerging from the column with fluorescamine. The products of this reaction are fluorescent and may be detected by an appropriate monitor. The advantage of the fluorescence-based system is that it is sensitive only to amine-containing analytes (nisin has four amine groups). This allows the analysis of nisin in complex formulations where other components interfere with the detection of nisin by absorption at 210 nm.

ii) Estimation of the minimum inhibitory concentration (MIC) of the nisin solution. This measures the functional activity of the nisin in the solution by testing its ability to kill or prevent the growth of a target bacterial population.

A series of two-fold dilutions of the solution of nisin to be tested is prepared. Aliquots of 5 μ l of these solutions are pipetted onto a lawn of target bacteria (*Staphylococcus aureus*) growing on a gel of nutrient agar in a petri dish. The dish is covered and incubated at 37°C overnight (~16 hr). Where the nisin concentration is sufficiently high to prevent growth of the bacteria there is a zone of clearance in the bacterial lawn. The activity of a nisin solution being tested is given as the lowest nisin

concentration inhibiting the growth of the bacteria (the minimum inhibitory concentration).

Example 1

5 Oral rinse formulations containing nisin were formulated with a variety of alternative components to determine which component(s) was associated with the degradation of the nisin. A series of formulations was prepared in which each component was omitted in turn.
10 These formulations and their components are set forth in Table 1. Residual nisin concentration is shown in $\mu\text{g/ml}$. The initial nisin concentration was 300 $\mu\text{g/ml}$.

A reference solution of nisin in 10 mM HCl was prepared as well as a full formulation with no omissions.
15 After incubation at room temperature for 3 days the formulations were analyzed by RPHPLC to determine the extent of degradation of the nisin.

Table 1

20 Residual Nisin Concentration In An Oral Rinse With Sequential Component Omission

	Component omitted	Nisin ($\mu\text{g/ml}$)	% Theoret- ical conc.
25 nisin standard		300	100
full formulation		206	69
	color FD&C Blue No. 1	189	63
	glycerol	223	74
	ethanol	154	51
	saccharin	163	54
	EDTA	149	50
	polysorbate	274	91
	Poloxamer 407	146	49
	flavor - coolmint (Noville)	154	51

Examination of the RPHPLC chromatograms for the formulations of Table 1 revealed that all the formulations showed accelerated nisin degradation relative to the reference in 10 mM HCl but that degradation was minimized in the formulations in which the polysorbate surfactant/emulsifier or the glycerol humectant were omitted.

Formulations of nisin useful as oral rinses comprising EDTA and the humectant glycerol were also prepared and analyzed by RPHPLC. These studies revealed a source of nisin degradation which was dependent on the simultaneous presence of both EDTA and glycerol in the formulation. Neither compound caused a problem in the absence of the other.

Glycerol and sorbitol from a number of sources, and a number of alternative chelators, were screened (Tables 2 and 3). No source of glycerol nor of sorbitol was found which was without effect on nisin stability in these formulations, and none of the chelating agents tested eliminated the problem, although citrate was superior to EDTA.

Table 2

Glycerol And Sorbitol Batches Screened For Effects On Nisin Stability

	Dow Glycerol	
30	P&G glycerol batches	# 925-371, #925-647, # 925-602
	Henkel glycerol batches	# ODG14, # OGG06, # OGG07
	Witco glycerol batches	# OU4314, # OR2245, # 9X5951
35	Pfizer sorbitol batches	# G06150, # G06200, # G06270
	Roquette sorbitol batches	# 4878, #4710, #4929

Table 3

5 Chelating Agents Screened For Effects On Nisin Stability

	EDTA	(ethylenediaminetetraacetic acid)
	EGTA	(ethyleneglycol-bis-(β -aminoethyl ether) N,N,N',N'-tetraacetic acid)
10	CDTA	(1,2-diaminocyclohexane N,N,N',N'-tetraacetic acid)
	DTPA	(diethylaminetriaminepentaacetic acid)
	HEEDTA	(N-hydroxyethylethylenediaminetriacetic acid)
	EDITEMPA	(N,N,N',N'-ethylenediaminetetra(methylene phosphonic acid))
15	citrate	

Example 2

In order to further analyze the nisin degradation
 20 associated with one particular surfactant/emulsifier,
 polysorbate, material was obtained from as many
 manufacturers as possible. Where possible, multiple
 production batches were obtained from each manufacturer.
 Other emulsifiers or surfactants believed to closely
 25 resemble polysorbate in their properties as well as
 dissimilar surfactants were also tested. An oral rinse
 formulation containing nisin was prepared using each of
 these compounds and, after incubation, samples were
 analyzed to evaluate nisin stability. The manufacturers
 30 and multiple batches of components tested are listed in
 Table 4.

Table 4

**Manufacturers And Batches Of Polysorbate Or Similar
Surfactants Tested For Use In Nisin Formulations.**

5	Lonza Polysorbate
	Heterene Hetsorb L20 P lots #18142, #20716, # 18410, #18546
	Mazer T-MAZ 20 lots #79779, #109104, #105655, #83371, #98372,
10	#96864, #95338, #95523, #82240, #80777
	Croda Crillet 1 lots #WB 1181, #WB1651DU, #WB1333DU
	ICI Tween 20, 40, 60, 65, 80, and 85
15	ICI Arlatone B
	ICI Arlatone G
	ICI Arlatone T
20	ICI Arlancel 165
	ICI Arlasolve 200

25 Great variation was observed in nisin stability in the
presence of the emulsifier/surfactants obtained from
different manufacturers; nisin stability was even markedly
different using different batches of the same product.
However, it was significant that all of the surfactants on
30 the extensive list tested accelerated nisin degradation to
some extent, relative to control formulations in which the
emulsifier/surfactant was omitted.

One possible explanation for this degradation may be
the introduction of substances during the manufacturing
35 process of formulation excipients. For example, to enhance
the appearance of polysorbate the product is bleached by
addition of peroxide, a well known oxidizing agent. It
seemed quite possible that the presence of residual peroxide
in polysorbate contributed to nisin instability. Nisin was
40 found to rapidly degrade on exposure to peroxide (Table 5).
Nisin was partially protected by the presence of EDTA. An

assay for peroxide was used to screen the various batches of polysorbate used in nisin formulations described herein, but no relationship could be seen between residual peroxide levels and nisin stability. Furthermore, samples taken from a production batch at Mazer Chemicals immediately prior to and immediately after the bleaching step were found to be equivalent in their effects on nisin stability. Thus peroxide added during manufacture may likely not be the agent of degradation.

Table 5

Residual nisin concentration ($\mu\text{g/ml}$) after 8 days at room temp. Initial nisin concentration was $300 \mu\text{g/ml}$. The concentration of NaOAc was 4mM and the concentration of Fe was $10 \mu\text{M}$.

	peroxide (μM)				glyceraldehyde (μM)			
	100	10	1	0	1000	100	10	0
NaOAc, Fe, peroxide	86	261	280	294				
EDTA, Fe, peroxide	170	273	297	303				
NaOAc, peroxide	154	263	289	283				
EDTA, peroxide	175	284	295					
NaOAc, glyceraldehyde					257	291	290	
EDTA, glyceraldehyde					273	289	285	

Example 3

A number of commonly used antioxidants were tested for their ability to protect nisin in formulation using the methods described in Example 2. The compounds and combinations tested are listed in Table 6. None of the compounds tested gave satisfactory protection of nisin. In fact some compounds in the list aggravated the stability problem, e.g., dithiothreitol (DTT), ascorbate, sodium sulfite.

Table 6
Commonly Used Antioxidants Tested For Protection
Of Nisin In Formulation.

5	butylated hydroxytoluene (BHT)
	butylated hydroxyanisole (BHA)
	propyl gallate
	alpha-tocopherol
10	phenylene-diamine
	ethoxyquin
	ascorbic acid
	citric acid
	hydroquinone
15	dithiothreitol (DTT)
	sodium sulfite
	BHA + BHT + propyl gallol + citric acid
	imidazole
	sodium thiosulfate
20	sodium benzoate

Example 4

25 The stabilization of nisin at 25 µg/ml by a range of
sulfur-containing compounds was evaluated in formulations
useful as topical germicides comprising polysorbate (T-
MAZ 20, Mazer Chemicals) with propyleneglycol, 1-
30 propanol, and either EDTA or citrate. In order to
expedite the execution of these experiments the
formulations were subjected to "stressed" conditions,
i.e., pH6 and 40°C, both intended to accelerate any
degradation effects taking place. The stability of nisin
35 in the formulations was evaluated by RPHPLC. The data in
Tables 7, 8 and 9 illustrate that the thioether
compounds, L- and DL-methionine, DL-methionine methyl- or
ethyl esters, and DL-methionine hydroxy analog are all
able to stabilize nisin from degradation. To a lesser
40 degree, nisin was also stabilized by the thioether
compounds thiazolidine and lanthionine. The disulfide
compounds cystine and oxidized glutathione, cysteic acid,
methionine sulfoxide and methionine sulfone, and the
sulfhydryl compound cysteine did not stabilize nisin from

degradation. In addition, the dibasic amino acid lysine did not stabilize nisin.

The stabilization of nisin by methionine in formulations useful as topical germicides where other emulsifier/surfactants were substituted for polysorbate was tested. Formulations were prepared with nisin at 25 $\mu\text{g/ml}$ and titrated to pH6. They were incubated at 40°C for 3 days and then analyzed by RPHPLC. The data in Table 10 illustrates that methionine also enhances nisin stability in formulations containing Brij, Tergitol, Tyloxapol, and Triton.

Table 7

Residual nisin concentration as a percentage of the theoretical concentration after 5 days at 40°C, pH 6

jd6-35-H	T-MAZ 20 Batch #	EDTA (mM)	Citrate %	con- trol	Met (1mM)	Lys (1mM)	CySH (1mM)
standar d				100			
33 - 36	357	1		87	84	80	85
37 - 40	357		0.1	73	75	71	29
41 - 44	357		0.3	71	76	71	36
45 - 48	357		1.0	67	73	71	31
49 - 52	348	1		55	80	56	51
53 - 56	348		0.1	49	76	45	36
57 - 60	348		0.3	49	73	47	29
61 - 64	348		1.0	51	73	49	33

Met = methionine; Lys = lysine; CySH = cysteine

Table 8

5 Residual nisin concentration after incubation for 2 weeks
at 40°C. Nisin Concentration ($\mu\text{g/ml}$)**

		T-MAZ 20 BATCH 357	T-MAZ 20 BATCH 348
	water control	19.5	9.5
10	methionine	23.2	23.3
	MHA	22.5	23.4
	cystine*	11.1	9.0
	cysteic acid	19.5	9.6
	glutathione (oxidized)	14.1	7.6
15	lanthionine	18.2	10.7
	thiazolidine	17.3	14.9

20 * Cystine at 5mM came out of solution as the pH was
raised to 3.5.

** Nisin was formulated at 25 $\mu\text{g/ml}$.

Table 9

Residual nisin concentration ($\mu\text{g/ml}$) after 6 days at 40°C.

5

10

15

20

Stabilizer	nisin ($\mu\text{g/ml}$)	T-MAZ 20 %
no methionine	10.1	1
DL-methionine	19.7	1
L-methionine	19.9	1
DL-methionine methyl ester	21.9	1
DL-methionine methyl ester	20.8	1
DL-methionine sulfoxide	8.6	1
DL-methionine sulfone	8.6	1
methionine hydroxy analog (Sigma)	18.1	1
methionine hydroxy analog (MHA Novus)	19.8	1
no stabilizer, no T-MAZ-20	21.8	0

* The initial concentration of nisin was 25 $\mu\text{g/ml}$.

Table 10

Stabilizing effect of methionine on nisin at 25 $\mu\text{g/ml}$ in a dermatological formulation under stressed conditions. Formulations were prepared at pH 6.0, substituting other surfactant agents for polysorbate (T-MAZ 20). Formulations were incubated for 3 days at 40°C to accelerate the degradation of nisin.

surfactant	no methionine	5mM methionine
T-MAZ 20	16.9	20.5
Brij	7.2	12.7
deoxycholic acid	20.0	20.3
Tergitol	3.8	9.7
Tyloxapol	10.0	19.4
Triton X-305	17.1	20.2
Triton X-100	8.9	12.1

Example 5

A series of tests was performed to determine the methionine concentration required for stabilization of nisin in a topical germicide formulation containing the polysorbate surfactant, T-MAZ 20, with methionine at concentrations in the range 0 to 5 mM. The stability of nisin in these formulations was compared to that of nisin in a formulation in which the polysorbate was omitted (Fig. 1).

A topical germicide formulation containing nisin was also prepared using the polysorbate T-MAZ 20 preincubated for the indicated times as a 10% solution containing methionine at 10 mM or 50 mM. Various preincubation mixtures were prepared and subjected to different preincubation time periods. Following preincubation, the treated mixture was diluted ten-fold when combined with nisin, resulting in a composition 1% in T-MAZ 20 and either 1 mM or 5 mM in methionine. The samples were then incubated at 40°C for 12 days and subsequently analyzed for nisin by RPHPLC. The results are shown in Fig. 2.

While there appears to be no advantage imparted to stabilization by preincubation, such a component preincubation manufacturing process may offer other advantages in terms of manufacturing efficiency, etc.

5 Example 6

A stabilized nisin formulation useful as an oral rinse was prepared as in Example 1 comprising a) polysorbate, b) glycerol or sorbitol, c) EDTA or citrate, and d) methionine in the concentrations as indicated in Table 11
10 below.

The formulations were adjusted to pH 4.0 and stored at 40°C. After 1 month samples were analyzed by RPHPLC. The estimated nisin concentration is shown in Table 11. Initial nisin concentration in the formulations was 100
15 µg/ml.

Table 11

Residual nisin concentrations in oral rinse formulations.

20

10% Humectant	EDTA (mM)	citrate (%)	methionine (mM)	Nisin (µg/ml)
sorbitol	1		0	88.9
25 sorbitol	1		1	94.1
sorbitol	1		2	97.7
glycerol	1		2	94.8
glycerol		0.3	2	84.9

30 Example 7

A stabilized nisin formulation useful as a deodorant was prepared using polysorbate T-MAZ 20 at pH 3.5, incubated for three (3) months at 40°C, and analyzed by
35 RPHPLC after 3 months. The results are presented in Table 12.

Table 12

Residual nisin concentration in deodorant formulations at
pH 3.5.

5

10

15

Sample No.	Ethanol	Tween	Met	Nisin*
	%	1 %	1mM	(μ g/ml)
		Batch #		
1	35	357		4.2
2	35	357	+	22.4
3	35	348		8.8
4	35	348	+	21.7
5	35	-		9.3
6	35	-	+	24.4

* Initial Nisin concentration was 25 μ g/ml. Nisin concentrations were determined by RPHPLC.

20

25

Deodorant formulations were also prepared with polysorbate T-MAZ 20 and methionine at 0, 1, 3, or 5 mM. Formulations were titrated to pH 3.5, 4.5, or 6.0 and set to incubate at 40°C. Samples were analyzed by RPHPLC after 5 days, 18 days, and 60 days. The estimated residual nisin concentration is shown in Table 13 below.

Table 13

Residual Nisin Concentration in Deodorant Formulations
at a Range of pH 3.5 to 6.0.

5		pH 3.5			pH 4.5			pH 6.0		
	days:	5	18	60	5	18	60	5	22	60
10	Met* (mM)	Nisin Concentration $\mu\text{g/ml}^{**}$								
	0	21.3	16.6	10.7	21.2	14.1	3.9	20.1	10.3	3.3
	1	23.7	21.7	16.2	22.7	21.6	13.4	22.1	18.6	11.9
	3	24.6	22.9	17.0	24.8	22.0	13.9	23.3	20.0	13.1
15	5	25.2	23.2	17.5	25.3	22.9	13.8	23.2	19.9	13.3

* Met = Methionine

** Initial nisin concentration was 25 $\mu\text{g/ml}$.

20

Example 8

Stable nisin formulations useful as topical
germicides were prepared at pH 3.5 and set to incubate at
25 40°C. After 2, 4, and 6 months samples were analyzed by
RPHPLC. At 6 months the samples were also analyzed for
activity in the MIC assay. The RPHPLC and MIC assay data
are presented in Table 14.

Table 14

Nisin concentration and MIC ($\mu\text{g/ml}$)
after 6 months at pH 3.5, 40°C.

5	EDTA	citrate	T-MAZ 20	Met	MIC	nisin conc.*
	1 mM	%	1%	1 mM	$\mu\text{g/ml}$	$\mu\text{g/ml}$
10	+				12.5	17.8
	+			+	12.5	22.2
	+		+		>50	11.5
	+		+	+	12.5	19.8
15		0.1			12.5	13.1
		0.1		+	12.5	18.1
		0.1	+		>50	3.0
		0.1	+	+	6.25	15.8
		0.3			12.5	13.6
		0.3		+	12.5	15.3
		0.3	+		>50	4.1
		0.3	+	+	3.125	14.8
20		1.0			25	7.7
		1.0		+	12.5	10.0
		1.0	+		12.5	2.5
		1.0	+	+	6.25	9.0
25						

* Initial nisin concentration was 25 $\mu\text{g/ml}$.

WE CLAIM:

1. A lanthionine-containing bacteriocin composition stabilized against degradation comprising a lanthionine-containing bacteriocin and a thioether stabilizing agent.
- 5 2. The composition of claim 1 wherein the bacteriocin is nisin.
3. A lanthionine-containing bacteriocin composition stabilized against degradation comprising a lanthionine-containing bacteriocin and a compound of the formula I
- 10
$$R^1-S-R^2 \quad (I)$$

wherein R^1 is an alkyl group containing 1-6 carbon atoms or $-(CH_2)_n-CH-COOH$

$$\begin{array}{c} | \\ NH_2 \end{array}$$
- 15 and R^2 is $-(CH_2)_n-CH-R^4$
- 20
$$\begin{array}{c} | \\ R^3 \end{array}$$

wherein n is 0 to 5; R^3 is hydrogen, an amino group or hydroxyl group; and R^4 is a hydrogen, a carboxyl group, an ester group or an amido group wherein the amino function

- 25 is contributed by an amino acid residue
- or wherein R^1 and R^2 together are joined to form, with the sulfur, a thiazolidine ring.
- 4. The composition of claim 3 wherein the composition
- 30 also comprises a surfactant.
- 5. The composition of claim 3 wherein the composition also comprises a chelating agent.
- 6. The composition of claim 3 wherein the bacteriocin is nisin.
- 35 7. The composition of claim 4 wherein the surfactant is a polysorbate.
- 8. The composition of claim 5 wherein the chelating agent is EDTA or citrate.
- 9. The composition of claim 3 wherein the compound of
- 40 formula I is methionine or methionine hydroxy analog.

10. The composition of claim 9 wherein the concentration of methionine is in the range of 1 to 50 mM.
11. The composition of claim 10 wherein the concentration of methionine is in the range of 1 to 10 mM.
12. A lanthionine-containing-bacteriocin composition stabilized against degradation comprising the bacteriocin in a concentration range of .1 to 1000 $\mu\text{g/ml}$, a surfactant in a concentration range of 0.1 - 10%, a chelating agent in a concentration range of 0.1 - 20 mM and a thioether stabilizing agent in a concentration range of 1 mM to 50 mM.
13. The composition of claim 12 wherein the bacteriocin is nisin and the stabilizing agent is methionine.
14. Use of a compound according to Formula I of claim 3 for stabilizing against degradation a lanthionine bacteriocin component of a composition.

FIG. 1





FIG. 2



INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 93/11884

A. CLASSIFICATION OF SUBJECT MATTER IPC 5 A01N63/02 //(A01N63/02,25:22,43:78)		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 5 A01N A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KOREAN J. ANIMAL SCI. vol. 27, no. 7, 1985, KOREA pages 480 - 483 SHIN HO LEE ET. AL. 'Studies on the antibiotic nisin produced by Streptococcus lactis IFO 12007 II. Activity of nisin against vegetative microbes and spore germination' see whole document ---	1-3,6, 9-13
A	WO,A,89 12399 (PUBLIC HEALTH RESEARCH INSTITUTE OF THE CITY OF NEW YORK) 28 December 1989 & US,A,5 135 910 (P.BLACKBURN ET. AL.) cited in the application --- -/--	
<div style="display: flex; justify-content: space-between;"> <input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex. </div>		
* Special categories of cited documents :		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>*A* document defining the general state of the art which is not considered to be of particular relevance</p> <p>*E* earlier document but published on or after the international filing date</p> <p>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*O* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>*&* document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search	Date of mailing of the international search report	
17 March 1994	21.03.94	
Name and mailing address of the ISA	Authorized officer	
European Patent Office, P.B. 3818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tr. 31 651 epo nl, Fax (+31-70) 340-3016	Donovan, T	

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 93/11884

C.(Continuation) D. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,90 09739 (THE PUBLIC HEALTH RESEARCH INSTITUTE OF THE CITY OF NEW YORK) 7 September 1990 ---	
A	EP,A,0 431 663 (AKZO N.V.) 12 June 1991 -----	

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Application No

PCT/US 93/11884

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-8912399	28-12-89	AU-B- 631803	10-12-92
		AU-A- 3843089	12-01-90
		EP-A- 0382814	22-08-90
		EP-A- 0545911	09-06-93
		JP-T- 3500051	10-01-91
		US-A- 5135910	04-08-92
		US-A- 5217950	08-06-93
		US-A- 5260271	09-11-93
US-A-5135910	04-08-92	AU-B- 631803	10-12-92
		AU-A- 3843089	12-01-90
		EP-A- 0382814	22-08-90
		EP-A- 0545911	09-06-93
		JP-T- 3500051	10-01-91
		WO-A- 8912399	28-12-89
		US-A- 5217950	08-06-93
		US-A- 5260271	09-11-93
WO-A-9009739	07-09-90	US-A- 4980163	25-12-90
		AU-B- 618714	02-01-92
		AU-A- 5285090	26-09-90
		CA-A- 2028140	02-09-90
		EP-A- 0424484	02-05-91
		JP-T- 3504864	24-10-91
EP-A-0431663	12-06-91	AU-B- 628768	17-09-92
		AU-A- 6779890	13-06-91
		DE-D- 69005992	24-02-94
		US-A- 5082864	21-01-92
		US-A- 5208261	04-05-93